Tumour

Manfred Georg Krukemeyer first describes magnetic drug targeting, by which is meant the focused application of drugs, e.g. the introduction of a cytostatic, and which is aimed at optimising its locally therapeutic effect. The author thus achieves a high concentration of cytostatic at the site of the tumour. The particles have to be large enough to be attracted by a magnetic field and so find their way into the tumour, where they release their active ingredient.

Authors: Escors, D., Talmadge, J.E., Breckpot, K., Van Ginderachter, J.A., Kochan, G.
Comprehensively explores the biology and role of MDSCs in cancer
Covers therapeutic targeting via the STAT3 pathway, a major regulatory pathway in MDSCs functions as well as in tumour cells
Particularly relevant for scientists working in the pharmaceutical industry and in oncology research